DelveInsight’s ‘Parkinson’s Disease Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and Parkinson’s Disease Pipeline therapies in various stages of Parkinson’s Disease clinical trial development, major pharmaceutical Parkinson’s Disease Companies are working to advance the Parkinson’s Disease pipeline space and future growth potential of the Parkinson’s Disease pipeline domain.
For Parkinson’s Disease emerging drugs, the Parkinson’s Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and Mechanism of Action. The Parkinson’s Disease pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key takeaways from the Parkinson’s Disease Pipeline Insight Report
- Over 140+ Parkinson’s Disease companies are evaluating 150+ Parkinson’s Disease pipeline therapies in various stages of development, and their anticipated acceptance in the Parkinson’s Disease market would significantly increase market revenue.
- The leading Parkinson’s Disease Companies includes Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
- Promising Parkinson’s Disease Pipeline Therapies includes Rotigotine, extended-release microspheres, LY03003 ( Rotigotine, extended-release microspheres), Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, VY-AADC02, CERE-120: AAV2-NTN, and others.
- The Parkinson’s Disease companies and academics that are working to assess challenges and seek opportunities that could influence Parkinson’s disease R&D. The Parkinson’s Disease pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.
Request a sample and discover the recent breakthroughs happening in Parkinson’s Disease Pipeline Landscape @ Parkinson’s Disease Pipeline Outlook Report
Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine. Studies have shown that symptoms of Parkinson’s develop in patients with an 80 percent or greater loss of dopamine-producing cells in the substantia nigra. Normally, dopamine operates in a delicate balance with other neurotransmitters to help coordinate the millions of nerve and muscle cells involved in movement. Without enough dopamine, this balance is disrupted, resulting in tremor (trembling in the hands, arms, legs and jaw); rigidity (stiffness of the limbs); slowness of movement; and impaired balance and coordination – the hallmark symptoms of Parkinson’s. The cause of Parkinson’s essentially remains unknown.
Parkinson’s disease Emerging Drugs Profile
- Tavapadon: Cerevel Therapeutics
Tavapadon was designed to improve motor symptoms in Parkinson’s disease by selectively targeting and binding to dopamine D1/D5 receptor subtypes. Tavapadon differentially activates the direct motor pathway, potentially driving motor benefit while minimizing side effects typical of drugs that non-selectively stimulate dopamine, such as daytime sedation, or somnolence, compromised impulse control and risk of psychotic symptoms including hallucinations. Tavapadon is also designed to activate the D1/D5 receptor subtypes at levels that maximize motor benefit while reducing the prolonged receptor overexcitation and desensitization caused by full agonists, which can lead to dyskinesias and exacerbation of “off” time. Currently, it is in Phase III stage of clinical trial evaluation to treat Parkinson disease.
- IkT-148009: Inhibikase Therapeutics
Inhibikase Therapeutics’ lead product candidate, IkT-148009, is a potent, selective small-molecule medication designed and engineered as chronically administered, once-daily oral medication targeting the underlying biological mechanism resulting in Parkinson’s disease, with the goal of halting disease progression and reversing functional loss. IkT-148009 is designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract by restoring neuroprotective mechanisms.
- NLY01: Neuraly
NLY01 is a proprietary long-acting analogue of exendin-4, a glucagon-like peptide-1 receptor (GLP-1R) agonist. NLY01 penetrates the blood-brain barrier (BBB) in animal models and its receptor (GLP-1R) is highly expressed on glial cells. NLY01 is being developed as a disease-modifying agent for neurodegenerative disorders including Parkinson’s and Alzheimer’s disease. In clinically relevant animal models, NLY01 was found to prevent neuronal cell death by inhibition of microglial activation and formation of A1 neurotoxic astroglial cells. Treatment with NLY01 slowed disease progression, improved motor and cognitive functions and extended the lifespan in mice with Parkinson’s disease.
- PT320: Peptron
PT320 is a sustained-release Exenatide (GLP1 agonist) for biweekly injection (Q2W). Due to its short half-life of 2.4 hours in the plasma of Exenatide, Peptron has developed a long-acting SR-Exenatide (PT320), resulting in sustained elevations of Exenatide for 20 days. With the result of preclinical and Phase I study of PT320, Peptron is testing the efficacy of PT320 of Parkinson’s disease in the on-going Phase II trial.
Find out more about the Parkinson’s Disease Diagnosis and Treatment of patients @ Parkinson’s Disease Ongoing Clinical Trials Analysis
Parkinson’s Disease Companies and Pipeline Therapies
- Cerevel Therapeutics: Rotigotine
- Inhibikase Therapeutics: extended-release microspheres
- Neuraly: LY03003 ( Rotigotine, extended-release microspheres)
- Peptron: Istradefylline 20 mg or 40 mg
- Biogen: LY3884961
- Roche: Methylprednisolone: Sirolimus
- Brain Neurotherapy Bio, Inc.: VY-AADC02
- Modag: CERE-120: AAV2-NTN
Parkinson’s Disease Pipeline Therapeutics Assessment
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Discover more about the list of FDA-approved drugs for Parkinson’s Disease @ Parkinson’s Disease Treatment Landscape
Scope of the Parkinson’s Disease Pipeline Report
- Coverage- Global
- Parkinson’s Disease Companies- Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd, and others.
- Parkinson’s Disease Pipeline Therapies- Rotigotine, extended-release microspheres, LY03003 ( Rotigotine, extended-release microspheres), Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, VY-AADC02, CERE-120: AAV2-NTN, and others.
- Parkinson’s Disease Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for Parkinson’s Disease Emerging Therapies and Ongoing Clinical Trials; visit @ Parkinson’s Disease Emerging Therapies and Companies
Table of Content
- Introduction
- Executive Summary
- Parkinson’s Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Parkinson’s Disease – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Tavapadon: Cerevel Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Prasinezumab : Roche
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- MEDI1341: AstraZeneca
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Neural microtissues: Treefrog Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Parkinson’s Disease Key Companies
- Parkinson’s Disease Key Products
- Parkinson’s Disease- Unmet Needs
- Parkinson’s Disease- Market Drivers and Barriers
- Parkinson’s Disease- Future Perspectives and Conclusion
- Parkinson’s Disease Analyst Views
- Parkinson’s Disease Key Companies
- Appendix
For further information on the Parkinson’s Disease Pipeline therapeutics, reach out @ Parkinson’s Disease Market Drivers and Barriers
Latest Blogs by DelveInsight
Latest Pharmaceuticals Market Research Reports 2023 by DelveInsight
Technical Due Diligence Firms | Radiation Retinopathy Market | Stem Cell Market | Anastomotic Leak Devices Market Oncolytic Virus Cancer Therapy Pipeline | Scabies Market | Shingles Market | Shigella Infections Market | Medical Marijuana Market | Lactose Intolerance Market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com